TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23607801

Group type: EXPERIMENTAL
Intervention: Using the Chinese language
Number of subjects: 512

Group type: COMPARATOR
Intervention: Using the English language
Number of subjects: 512
Study: 22500081

Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight fraction of edible mushroom shiitake extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (negative control without active ingredients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meridol (positive control, AmF‐SnF(2))
Number of subjects: 0
Study: 20510862

Group type: EXPERIMENTAL
Intervention: Model-based reinforcement learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-free reinforcement learning
Number of subjects: 0
Study: 18575277

Group type: EXPERIMENTAL
Intervention: 100-g OGTT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 75-g OGTT
Number of subjects: 41
Study: 15909229

Group type: EXPERIMENTAL
Intervention: Omnilux Revive facial treatment (20 min treatments, three times a week for three weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Omnilux Revive facial treatment
Number of subjects: 23
Study: 12217597

Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg IV + Prednisone 40 mg/day for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + Prednisone 40 mg/day for 28 days
Number of subjects: 20
Study: 9929018

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 225
Study: 7779142

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.) and Indometacin (25 mg b.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nimodipine monotherapy
Number of subjects: 24
Study: 2087857

Group type: EXPERIMENTAL
Intervention: Interval training (1:1 min work and interval)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous training
Number of subjects: 18
Study: 6253067

Group type: COMPARATOR
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks) and CCNU (70 mg/m2 every 6 weeks)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m2 every 3 weeks), CCNU (70 mg/m2 every 6 weeks), and doxorubicin (40 mg/m2 every 3 weeks)
Number of subjects: 124
Study: 30612237

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study: 28338206

Group type: EXPERIMENTAL
Intervention: Embosphere microsphere artery embolization
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (healthy cases)
Number of subjects: 128
Study: 25985708

Group type: EXPERIMENTAL
Intervention: Standardized treadmill exercise test
Number of subjects: 248
Study: 23046274

Group type: EXPERIMENTAL
Intervention: Self-chosen brief motivational intervention (BMI)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Self-chosen computer-delivered educational program
Number of subjects: 288

Group type: COMPARATOR
Intervention: Researcher-assigned brief motivational intervention (BMI)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Researcher-assigned computer-delivered educational program
Number of subjects: 288
Study: 21416145

Group type: EXPERIMENTAL
Intervention: Golfers
Number of subjects: 23

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 23
Study: 19351731

Group type: EXPERIMENTAL
Intervention: l-arginine/GHRH infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: l-arginine/GHRP-2 infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Abdominal visceral fat (AVF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AVF
Number of subjects: 22
Study: 18843793

Group type: EXPERIMENTAL
Intervention: Moderate protein restriction (0.95 g kg(‐1) of body weight per day) for 3 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Severe calorie restriction without malnutrition
Number of subjects: 6
Study: 16014883

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study: 12409984

Group type: EXPERIMENTAL
Intervention: Fasudil 5 mg TID
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fasudil 10 mg TID
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fasudil 20 mg TID
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fasudil 40 mg TID
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fasudil (various doses)
Number of subjects: 170
Study: 10461605

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 38
Study: 7625349

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) diets
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RS-supplemented diets
Number of subjects: 6
Study: 2664140

Group type: COMPARATOR
Intervention: Olympia alloy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Alternative alloys (W‐1, Ceramalloy II, Micro‐Bond N/P2, Ticon)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Unrestored tooth (periodontal control)
Number of subjects: 800
Study: 409315

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium, administered for four weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 12
Study: 31399275

Group type: EXPERIMENTAL
Intervention: Adjuvanted 0.5 μg total viral protein (TP) with Al(OH)3
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Adjuvanted 1.0 μg total viral protein (TP) with Al(OH)3
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 1.0 μg total viral protein (TP)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Safety profile monitoring
Number of subjects: 135
Study: 29229209

Group type: COMPARATOR
Intervention: AV-101 (l-4-chlorokynurenine) at doses of 30-1800mg (Phase 1A) and 360, 1080, 1440mg/day (Phase 1B) administered orally for 14 days.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo administered orally for 14 days.
Number of subjects: 86
Study: 25646645

Group type: EXPERIMENTAL
Intervention: Health care-seeking behaviour of HIV-infected mothers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Health care-seeking behaviour of male partners
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Infant care-seeking behaviour
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Strategies to improve health care access
Number of subjects: 32
Study: 23241479

Group type: EXPERIMENTAL
Intervention: Oral and implant naltrexone
Number of subjects: 68
Study: 19593797

Group type: EXPERIMENTAL
Intervention: R-CHOP + bortezomib (Arm A: 1 mg/m²; Arm B: 1.3 mg/m²)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: R-CHOP + bortezomib (Arm A: 1.3 mg/m²; Arm B: 1.6 mg/m²)
Number of subjects: 49
Study: 17073835

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 600
Study: 15119909

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ) at a mean dose of 756.44 mg/day
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11944742

Group type: EXPERIMENTAL
Intervention: Johnstone Pressure Splints
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neuromuscular rehabilitation
Number of subjects: 26
Study: 9143576

Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Jejunal S-shaped pouch
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 64
Study: 8112490

Group type: EXPERIMENTAL
Intervention: Somatostatin and octreotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct control of the wedged hepatic vein pressure gradient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevention of recurrent hemorrhage
Number of subjects: 0
Study: 2467135

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5.0 mg (medium-dose group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine 5.0-10.0 mg (high-dose group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine 1.25-2.5 mg (low-dose group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29569754

Group type: EXPERIMENTAL
Intervention: Synthetic bone substitute covered with a collagen membrane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blood clot covered with a collagen membrane
Number of subjects: 15
Study: 28349344

Group type: EXPERIMENTAL
Intervention: Multi-session intensive telephone counseling
Number of subjects: 384

Group type: COMPARATOR
Intervention: Referral to state quitline counseling
Number of subjects: 384
Study: 26476466

Group type: EXPERIMENTAL
Intervention: BreastCARE intervention
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1235
Study: 24568169

Group type: EXPERIMENTAL
Intervention: Water flosser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional string floss
Number of subjects: 40
Study: 21353674

Group type: EXPERIMENTAL
Intervention: L-menthol (160 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17955021

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17072702

Group type: EXPERIMENTAL
Intervention: 150 microg oral clonidine and 20 mg raftidine (clonidine group; n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 20 mg raftidine only (control group; n = 41)
Number of subjects: 82
Study: 14574247

Group type: EXPERIMENTAL
Intervention: Explant technique of scleral buckling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implant technique of scleral buckling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both implant and explant techniques
Number of subjects: 0
Study: 10997364

Group type: EXPERIMENTAL
Intervention: Single oral dose of 100,000 IU vitamin A
Number of subjects: 120
Study: 8959519

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) plus Amoxycillin (750 mg t.i.d.) for 2 weeks
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg b.i.d.) plus Clarithromycin (500 mg t.i.d.) for 2 weeks
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Second consecutive dual therapy (either omeprazole plus amoxycillin or omeprazole plus clarithromycin)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Overall eradication rates
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Patients with gastric ulcer (GU)
Number of subjects: 450
Study: 1526681

Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) 1 g i.m. b.i.d. for eight days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4089792

Group type: COMPARATOR
Intervention: Heparin alone (Hep)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Heparin + dihydroergotamine (DHE-Hep)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Heparin + sulphinpyrazone (Sulph-Hep)
Number of subjects: 358
Study: 29456238

Group type: EXPERIMENTAL
Intervention: Primary PCI+RIPC
Number of subjects: 80
Study: 27483317

Group type: EXPERIMENTAL
Intervention: Protein-pacing caloric-restriction (P-CR; 6 meals/day, >30% protein/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified protein-pacing caloric-restriction (mP-CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heart healthy (HH) diet (3 meals/day, 15% protein/day)
Number of subjects: 40
Study: 24113340

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation on the left premotor cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of high-frequency repetitive transcranial magnetic stimulation and traditional eye-hand integration training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional eye-hand integration training
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency repetitive transcranial magnetic stimulation on the right premotor cortex
Number of subjects: 0
Study: 22072742

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 361

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 361
Study: 20685066

Group type: EXPERIMENTAL
Intervention: Four Habits Coding Scheme (4HCS)
Number of subjects: 497
Study: 18195202

Group type: EXPERIMENTAL
Intervention: Ergocalciferol, 1000 IU/d, plus calcium citrate, 1000 mg/d
Number of subjects: 302

Group type: COMPARATOR
Intervention: Calcium citrate, 1000 mg/d (control group)
Number of subjects: 302
Study: 15903123

Group type: COMPARATOR
Intervention: Moxifloxacin (QT-positive control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alfuzosin (40 mg)
Number of subjects: 48
Study: 12553387

Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), cisatracurium (0.1 mg kg(‐1))
Number of subjects: 39
Study: 10750600

Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat less than once per week
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat once per week
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat 2-4 times per week
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Exercise vigorous enough to work up a sweat 5+ times per week
Number of subjects: 22071
Study: 8668409

Group type: EXPERIMENTAL
Intervention: Dust control intervention (cleaning supplies, information, and demonstration)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (brochure about lead poisoning prevention)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dust control intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 1893699

Group type: EXPERIMENTAL
Intervention: Female condom (Reality)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 30
Study: 6222756

Group type: EXPERIMENTAL
Intervention: I% metronidazole cream
Number of subjects: 51

Group type: COMPARATOR
Intervention: 250 mg oxytetracycline tablets taken twice daily
Number of subjects: 51
Study: 31138221

Group type: EXPERIMENTAL
Intervention: High-fat meal immediately following 1 h of moderate exercise (65% maximal heart rate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat meal alone (resting control)
Number of subjects: 12
Study: 28625512

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 169
Study: 26039949

Group type: EXPERIMENTAL
Intervention: Stretching with Valsalva maneuver
Number of subjects: 15

Group type: COMPARATOR
Intervention: Stretching without Valsalva maneuver
Number of subjects: 15
Study: 23615791

Group type: EXPERIMENTAL
Intervention: TB‐402 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TB‐402 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban 10 mg
Number of subjects: 0
Study: 22058101

Group type: EXPERIMENTAL
Intervention: 10 mg dalfampridine under fasted condition (no food for 10-12 hours)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg dalfampridine under fed condition (after a high-fat meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adverse events reported by participants
Number of subjects: 30
Study: 18667112

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention for 18 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 140
Study: 17537085

Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy with Burch colposuspension
Number of subjects: 322

Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy without Burch colposuspension
Number of subjects: 322
Study: 15565080

Group type: EXPERIMENTAL
Intervention: Meal 1A (plain porridge with lean pork)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Meal 3A (plain noodles in clear soup)
Number of subjects: 24
Study: 15222825

Group type: EXPERIMENTAL
Intervention: Implementation intentions for home blood glucose monitoring, 4 times daily for 3 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Rehearsed or deliberated (comparison groups)
Number of subjects: 31
Study: 10909485

Group type: EXPERIMENTAL
Intervention: NAT2* genotype (slow acetylation)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Healthy controls (no NAT2* genotype)
Number of subjects: 266
Study: 8547077

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rhIL-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg rhIL-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg rhIL-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5 micrograms/kg rhIL-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rhIL-3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses of rhIL-3
Number of subjects: 30
Study: 2023200

Group type: EXPERIMENTAL
Intervention: Inservice education for PHN
Number of subjects: 37

Group type: COMPARATOR
Intervention: Public and physician information interventions
Number of subjects: 37
Study: 6111216

Group type: EXPERIMENTAL
Intervention: Positive-pressure tympanograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type B tympanograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihistamine-decongestant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31881952

Group type: EXPERIMENTAL
Intervention: Supervised training (FA), n=53, 50-min exercise circuit including strength and aerobic exercises, complemented with 30-min brisk walking on the third day.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Self-directed physical activity (DA), n=43.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Physically inactive (PI), n=48.
Number of subjects: 144
Study: 28373244

Group type: EXPERIMENTAL
Intervention: Intracoronary morphine (3 mg of morphine sulfate diluted with 3 mL of normal saline)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (3 mL of normal saline)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intracoronary morphine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study: 27124841

Group type: EXPERIMENTAL
Intervention: CICADA method (ceasing CPAP with a view to remain off rather than slow weaning)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: CICADA method
Number of subjects: 270
Study: 25149705

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg per day (Q100)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CoQ10 300 mg per day (Q300)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21999406

Group type: EXPERIMENTAL
Intervention: Combined perianal-intrarectal lidocaine-prilocaine cream and lidocaine-ketorolac gel
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combined perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block
Number of subjects: 200
Study: 19084425

Group type: EXPERIMENTAL
Intervention: Haemofiltration during cardiopulmonary bypass (CPB)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No haemofiltration during cardiopulmonary bypass (CPB)
Number of subjects: 79
Study: 17884370

Group type: EXPERIMENTAL
Intervention: Eptifibatide alone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Eptifibatide plus UFH
Number of subjects: 159
Study: 15212194

Group type: EXPERIMENTAL
Intervention: Laser needle acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Laser needle acupuncture (females)
Number of subjects: 29
Study: 12475427

Group type: EXPERIMENTAL
Intervention: Indomethcin rinse
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19
Study: 9860085

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg b.i.d.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Prednisolone (40 mg on day 1 decreased to 5 mg on day 7)
Number of subjects: 81
Study: 7543605

Group type: EXPERIMENTAL
Intervention: Free PSA
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Complexed PSA
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Total PSA
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Free-to-total PSA ratio
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Complexed-to-total PSA ratio
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Free-to-complexed PSA ratio
Number of subjects: 422
Study: 31331569

Group type: EXPERIMENTAL
Intervention: Massage with topical 5 ml violet oil for 7 min during six sessions (two weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Massage alone (without violet oil) for 7 min during six sessions (two weeks)
Number of subjects: 57
Study: 28820681

Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced heat therapy (RFHT) at 50°C for 30 seconds
Number of subjects: 213

Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (IL‐SSG) 1-3 mL given weekly until cure/10 doses
Number of subjects: 213
Study: 26071690

Group type: EXPERIMENTAL
Intervention: Unipedicular PVP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bipedicular PVP
Number of subjects: 50
Study: 23167738

Group type: EXPERIMENTAL
Intervention: Sealed-capsule irrigation (SCI) using distilled water (DW) for 3 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mechanical cleaning (MC) of the capsular bag
Number of subjects: 60
Study: 20472172

Group type: EXPERIMENTAL
Intervention: Alteplase (rt-PA)
Number of subjects: 3670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3670
Study: 17546453

Group type: EXPERIMENTAL
Intervention: AW group (additional water intake; n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NW group (no additional water intake; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AW group
Number of subjects: 60